Baillie Gifford & Co. Sells 55,936 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Baillie Gifford & Co. trimmed its position in Edwards Lifesciences by 9.8% in Q4, selling 55,936 shares and now holds 516,311 shares (~0.09% of the company) valued at about $44.02 million.
• Insiders have been net sellers: the CFO sold 13,000 shares and company insiders sold a total of 86,058 shares worth roughly $7.12 million in the past three months.
• Analysts carry a "Moderate Buy" consensus with an average target of $95.74; the stock trades near $78 (market cap $44.98B, P/E 42.6) after Edwards missed Q4 EPS by $0.04 but beat revenue and issued Q1 EPS guidance of $0.70–$0.76.

Baillie Gifford & Co. lessened its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 9.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 516,311 shares of the medical research company's stock after selling 55,936 shares during the quarter. Baillie Gifford & Co. owned about 0.09% of Edwards Lifesciences worth $44,016,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $25,000. True Wealth Design LLC raised its stake in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock worth $28,000 after acquiring an additional 259 shares in the last quarter. Hantz Financial Services Inc. raised its stake in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company's stock worth $29,000 after acquiring an additional 164 shares in the last quarter. Dorato Capital Management bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $29,000. Finally, Rakuten Securities Inc. raised its stake in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on EW shares. The Goldman Sachs Group reissued a "buy" rating and set a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the stock a "hold" rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. Finally, Wolfe Research raised shares of Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 target price on the stock in a research report on Wednesday, April 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $95.74.

Edwards Lifesciences Stock Up 0.2%

EW stock opened at $78.02 on Tuesday. The firm's fifty day simple moving average is $81.32 and its 200-day simple moving average is $82.06. The company has a market capitalization of $44.98 billion, a P/E ratio of 42.63, a price-to-earnings-growth ratio of 2.03 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences Corporation has a 12 month low of $68.63 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion during the quarter, compared to analysts' expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm's revenue was up 13.3% on a year-over-year basis. During the same period last year, the company earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of the business's stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at $3,177,507.96. The trade was a 24.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the business's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the transaction, the vice president owned 33,934 shares of the company's stock, valued at approximately $2,747,975.32. This represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 86,058 shares of company stock worth $7,118,636 in the last three months. Company insiders own 0.31% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.